The investigators hypothesize that positron emission tomography with fluorocholline (F18-choline PET) will reduce the proportion of unnecessary invasive surgery decisions and that the higher cost of positron emission tomography versus MIBI scintigraphy (Tc99m-sestaMIBI ) will be offset by lower cost in terms of type. surgery performed wisely and complications.

Inclusion Criteria:

• Patient 18 years old
• Patient presenting with primary hyperparathyroidism and for whom an excisional surgery is planned
• For women of childbearing age, negative pregnancy test at Baseline
• Biological assessment confirming the diagnosis of primary hyperparathyroidism (high serum PTH and calcium concentrations)
• Affiliation to a social security scheme
• Patient having signed his written consent

Exclusion Criteria:

• Patient deprived of liberty, under tutorship or curatorship
• Hypersensitivity to TECNESCAN SESTAMIBI
• Any associated medical or psychological condition that could compromise the patient's ability to participate in the study
• Pregnant or lactating woman
• History of parathyroid surgery
• Patient with multiple endocrine neoplasia 1 (NEM1)
• Known hypersensitivity to fluorocholine or to any of the excipients (sodium chloride, water for injections)